WEED, Inc. Posts $1.37M Loss and Flags Going Concern Risk
Financial instability cannabis companies face can disrupt patient access to consistent, quality-controlled cannabis products. WEED, Inc. recently reported a $1.37 million loss and flagged going concern risks. This highlights broader financial pressures…
FDA Grants Limited Enforcement Discretion for CBD in Dietary Supplements
FDA enforcement discretion CBD policy marks a new regulated pathway for dietary supplements in the U.S. This shift may improve product quality oversight and patient access. Clinicians should understand these changes to guide patient care effectively.
High Moon Wellness Launches Online Store: Premium CBD Recovery for Athletes
Athletic CBD recovery is gaining attention as High Moon Wellness launches an online store offering premium CBD products. These products target athletes seeking recovery and wellness benefits. However, clinical evidence for CBD's efficacy in athletic…
Ensuring CBD Gummy Patient Safety for Anxiety
CBD gummy patient safety is crucial when considering treatment for anxiety disorders. Clinicians must evaluate product quality and dosing consistency to ensure safe use. Evidence-based information guides patient care decisions regarding CBD gummies for…
Fight Over Cannabis Testing and Tracking Bill Picks Up Steam
Cannabis testing standards remain a critical issue affecting product quality and patient safety. Regulatory debates focus on establishing consistent testing protocols for medical cannabis. These standards directly impact clinical predictability and…
How 2026 CBD Enforcement Policy Changes Are Shaping Cannabis Stocks
2026 CBD enforcement policy changes are reshaping the cannabis market landscape. Reduced FDA enforcement may improve patient access but raises concerns about product quality. Clinicians must guide patients on safe CBD use amid evolving regulations.
Züri Can Extended By Two Years As Results Point To Black Market Deterrence
The 2026 cannabis black market deterrence is supported by the Züri Can pilot program's extension. This program offers regulated cannabis access with tested products, improving patient safety. Clinicians should note the importance of product quality in…
Tilray Brands’ Strong Cannabis Sales and Upbeat Outlook Keep Analysts Bullish
Tilray Brands strong cannabis sales demonstrate significant cannabis market growth. This growth suggests improved product availability and market stability for patients. Robust sales may also encourage increased cannabis research funding.
Top 15 Companies in Global Cannabidiol (CBD) Consumer Health Market Size
The global cannabidiol consumer health market is rapidly evolving with key companies driving product quality and clinical reliability. Understanding market leaders helps clinicians recommend consistent CBD products. This article highlights the top 15…
Understanding New Hemp Regulatory Changes
Hemp regulatory changes directly impact product availability, quality standards, and legal clarity for patients using CBD and hemp-derived cannabinoids. Clinicians must understand evolving compliance requirements to guide patient access effectively.…